About: Terutroban     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:SulfaDrug104352070, within Data Space : dbpedia.org associated with source document(s)
QRcode icon
http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FTerutroban&graph=http%3A%2F%2Fdbpedia.org&graph=http%3A%2F%2Fdbpedia.org

Terutroban is an antiplatelet agent developed by Servier Laboratories. It is a selective thromboxane prostanoid (TP) antagonist and is an orally active drug in clinical development for the secondary prevention of acute thrombotic complications. Researchers from the University of Milan also found in a new research that terutroban can prevent the development of aorta hyperplasia and has beneficial effects on fibrotic processes, leading to the conclusion that it has beneficial effects in preventing or retarding atherogenesis.

AttributesValues
rdf:type
rdfs:label
  • تيروتروبان (ar)
  • Terutroban (en)
  • Terutroban (pt)
rdfs:comment
  • تيروتروبان هو عامل مضاد للصفيحات وضعت من قبل مختبرات سيرفير. وقد تم اختباره للوقاية الثانوية من المضاعفات الحادة في المرحلة الثالثة من التجارب السريرية PERFORM (الوقاية من الأمراض القلبية الوعائية والقلبية والأوعية الدموية مع تيروتروبان في المرضى الذين يعانون من التقرح الدماغي أو الجلطة الدماغية أو الشق الجراحي) تم إيقاف الدراسة قبل الأوان، وبالتالي لا يمكن تحديد ما إذا كان تيروتروبان له تأثير أفضل من الأسبرين. (ar)
  • Terutroban é um agente antiplaquetário desenvolvido pelos laboratórios Servier. Desde 2008 é testado para a prevenção secundária de complicações trombóticas agudas no ensaio clínico de Fase III PERFORM. Terutroban é um antagonista seletivo dos receptores de tromboxano. (pt)
  • Terutroban is an antiplatelet agent developed by Servier Laboratories. It is a selective thromboxane prostanoid (TP) antagonist and is an orally active drug in clinical development for the secondary prevention of acute thrombotic complications. Researchers from the University of Milan also found in a new research that terutroban can prevent the development of aorta hyperplasia and has beneficial effects on fibrotic processes, leading to the conclusion that it has beneficial effects in preventing or retarding atherogenesis. (en)
foaf:depiction
  • http://commons.wikimedia.org/wiki/Special:FilePath/Terutroban_acid_skeletal.svg
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
sameAs
dbp:wikiPageUsesTemplate
thumbnail
ATC prefix
  • none (en)
c
CAS number
ChemSpiderID
Cl
elimination half-life
H
IUPAC name
legal status
  • Investigational (en)
n
O
PubChem
routes of administration
  • Oral (en)
s
SMILES
  • CC1=CCCCO (en)
StdInChI
StdInChIKey
  • HWEOXFSBSQIWSY-MRXNPFEDSA-N (en)
UNII
  • A6WX9391D8 (en)
Verifiedfields
  • changed (en)
verifiedrevid
Watchedfields
  • changed (en)
has abstract
  • تيروتروبان هو عامل مضاد للصفيحات وضعت من قبل مختبرات سيرفير. وقد تم اختباره للوقاية الثانوية من المضاعفات الحادة في المرحلة الثالثة من التجارب السريرية PERFORM (الوقاية من الأمراض القلبية الوعائية والقلبية والأوعية الدموية مع تيروتروبان في المرضى الذين يعانون من التقرح الدماغي أو الجلطة الدماغية أو الشق الجراحي) تم إيقاف الدراسة قبل الأوان، وبالتالي لا يمكن تحديد ما إذا كان تيروتروبان له تأثير أفضل من الأسبرين. (ar)
  • Terutroban is an antiplatelet agent developed by Servier Laboratories. It is a selective thromboxane prostanoid (TP) antagonist and is an orally active drug in clinical development for the secondary prevention of acute thrombotic complications. It has been tested in the Phase III clinical trial PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack). The study was prematurely stopped and it could not be determined whether terutroban has a better effect than aspirin. The 2011 clinical trial that studied the antiplatelet agent versus aspirin found that it was not superior in the prevention of cerebral and cardiovascular ischaemic events, although it was significantly better in patients who already suffered previous stroke to the qualifying event. Researchers from the University of Milan also found in a new research that terutroban can prevent the development of aorta hyperplasia and has beneficial effects on fibrotic processes, leading to the conclusion that it has beneficial effects in preventing or retarding atherogenesis. (en)
  • Terutroban é um agente antiplaquetário desenvolvido pelos laboratórios Servier. Desde 2008 é testado para a prevenção secundária de complicações trombóticas agudas no ensaio clínico de Fase III PERFORM. Terutroban é um antagonista seletivo dos receptores de tromboxano. (pt)
gold:hypernym
prov:wasDerivedFrom
page length (characters) of wiki page
CAS number
  • (sodiumsalt)
  • 165538-40-9
FDA UNII code
  • A6WX9391D8
PubChem
  • 9938840
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (62 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software